216 related articles for article (PubMed ID: 24410765)
1. Inhibitory effects of aromatase inhibitor on estrogen receptor-alpha positive ovarian cancer in mice.
Hirakawa H; Yokoyama Y; Yoshida H; Mizunuma H
J Ovarian Res; 2014 Jan; 7():4. PubMed ID: 24410765
[TBL] [Abstract][Full Text] [Related]
2. Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Banerjee S; A'Hern R; Detre S; Littlewood-Evans AJ; Evans DB; Dowsett M; Martin LA
Clin Cancer Res; 2010 Aug; 16(16):4178-87. PubMed ID: 20682704
[TBL] [Abstract][Full Text] [Related]
3. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D; Sabnis G; Long BJ; Macedo L; Goloubeva OG; Brodie AM
Cancer Res; 2005 Jun; 65(12):5380-9. PubMed ID: 15958587
[TBL] [Abstract][Full Text] [Related]
4. Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts.
Andreucci E; Francica P; Fearns A; Martin LA; Chiarugi P; Isacke CM; Morandi A
Oncotarget; 2016 Dec; 7(49):80543-80553. PubMed ID: 27602955
[TBL] [Abstract][Full Text] [Related]
5. Expression of estrogen-related gene markers in breast cancer tissue predicts aromatase inhibitor responsiveness.
Moy I; Lin Z; Rademaker AW; Reierstad S; Khan SA; Bulun SE
PLoS One; 2013; 8(11):e77543. PubMed ID: 24223121
[TBL] [Abstract][Full Text] [Related]
6. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
7. Aromatase inhibitors and xenograft studies.
Chumsri S; Sabnis GJ; Howes T; Brodie AM
Steroids; 2011 Jul; 76(8):730-5. PubMed ID: 21420993
[TBL] [Abstract][Full Text] [Related]
8. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
Yokoyama Y; Xin B; Shigeto T; Mizunuma H
J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
[TBL] [Abstract][Full Text] [Related]
9. Understanding resistance to endocrine agents: molecular mechanisms and potential for intervention.
Sabnis G; Brodie A
Clin Breast Cancer; 2010 Feb; 10(1):E6-E15. PubMed ID: 20133251
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
11. Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A; Brodie AM; Njar VC
Cancer Res; 2006 Dec; 66(23):11485-93. PubMed ID: 17145897
[TBL] [Abstract][Full Text] [Related]
12. Stopping treatment can reverse acquired resistance to letrozole.
Sabnis GJ; Macedo LF; Goloubeva O; Schayowitz A; Brodie AM
Cancer Res; 2008 Jun; 68(12):4518-24. PubMed ID: 18559495
[TBL] [Abstract][Full Text] [Related]
13. Aromatase expression in ovarian epithelial cancers.
Cunat S; Rabenoelina F; Daurès JP; Katsaros D; Sasano H; Miller WR; Maudelonde T; Pujol P
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):15-24. PubMed ID: 15748828
[TBL] [Abstract][Full Text] [Related]
14. Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Sabnis GJ; Goloubeva O; Chumsri S; Nguyen N; Sukumar S; Brodie AM
Cancer Res; 2011 Mar; 71(5):1893-903. PubMed ID: 21245100
[TBL] [Abstract][Full Text] [Related]
15. Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I; Itoh T; Chen S
J Steroid Biochem Mol Biol; 2005 Dec; 97(4):360-8. PubMed ID: 16263272
[TBL] [Abstract][Full Text] [Related]
16. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D; Macedo L; Goloubeva OG; Handratta V; Brodie AM
Cancer Res; 2005 Jun; 65(12):5439-44. PubMed ID: 15958593
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to the aromatase inhibitor letrozole is prolonged after a "break" in treatment.
Sabnis G; Goloubeva O; Gilani R; Macedo L; Brodie A
Mol Cancer Ther; 2010 Jan; 9(1):46-56. PubMed ID: 20053764
[TBL] [Abstract][Full Text] [Related]
18. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
Wang J; Gildea JJ; Yue W
Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of calcitriol on the growth of MCF-7 breast cancer xenografts in nude mice: selective modulation of aromatase expression in vivo.
Swami S; Krishnan AV; Wang JY; Jensen K; Peng L; Albertelli MA; Feldman D
Horm Cancer; 2011 Jun; 2(3):190-202. PubMed ID: 21686077
[TBL] [Abstract][Full Text] [Related]
20. The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J; Pornon A; Chen B; Chen S; Evans DB
Breast Cancer Res; 2008; 10(4):R56. PubMed ID: 18611244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]